MAM
BMRN icon

Must Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Must Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,779
Closed -$604K – 55
2021
Q4 		$604K Hold
6,779
– – 0.32% 32
2021
Q3 		$520K Hold
6,779
– – 0.34% 27
2021
Q2 		$566K Sell
6,779
-4,328
-39% -$343K 0.4% 21
2021
Q1 		$833K Hold
11,107
– – 0.65% 21
2020
Q4 		$966K Buy
+11,107
New +$881K 0.69% 20

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Must Asset Management's BMRN Position: Q1 2022 in Review

Must Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 6,779 shares — an estimated $604K sold.

Must Asset Management first reported a position in BMRN in Q4 2020 and held it in 5 quarters. The position peaked at $966K in Q4 2020. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Must Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Must Asset Management sold 6,779 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $604K.
  • Must Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Must Asset Management's BioMarin Pharmaceuticals position peaked at $966K in Q4 2020.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Must Asset Management's 13F filing for Q1 2022, filed 11 May 2022.